Furthermore, in resistant cancer cells, activation of a non-classical YAP1-TEAD2 axis mediated by HER4 is closely associated with drug resistance, and combining HER inhibitors (e.g., lapatinib) may reverse resistance to trastuzumab (González-Alonso et al., 2020; Mehra et al., 2011). The gene discussed is YAP1; the disease is cancer.